July 6, 2020 / 6:36 AM / a month ago

BRIEF-Medivir And SciLifeLab Enter Collaboration On Potential SARS CoV-2 Inhibitors

July 6 (Reuters) - Medivir AB:

* MEDIVIR AND SCILIFELAB ENTER COLLABORATION ON POTENTIAL SARS COV-2 INHIBITORS

* DDD WILL GET ACCESS TO MEDIVIR’S UNIQUE PROPRIETARY PROTEASE-TARGETED COMPOUND LIBRARY.

* THROUGH COLLABORATION, DDD WILL GET ACCESS TO MEDIVIR’S UNIQUE PROPRIETARY PROTEASE-TARGETED COMPOUND LIBRARY.

* RESEARCH COLLABORATION WITH DRUG DISCOVERY AND DEVELOPMENT PLATFORM (DDD) AT SCILIFELAB ON POTENTIAL INHIBITORS OF SARS COV-2.

* AIM OF COLLABORATION IS TO FIND POTENTIAL INHIBITORS OF MAIN PROTEASE OF SARS COV-2,

* DATA FOR UP TO 100 TOP-INHIBITORS WILL BE RELEASED ON-LINE AND WILL BE FREELY AVAILABLE FOR DRUG DEVELOPMENT TO COMBAT COVID-19

* PROJECT IS PART OF NATIONAL COVID-19 RESEARCH PROGRAM AT SCILIFELAB, WHICH IS FUNDED BY KNUT AND ALICE WALLENBERG FOUNDATION WITH A TOTAL OF 50 MSEK Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below